Previous Close | 0.3600 |
Open | 0.3650 |
Bid | 0.3650 x 0 |
Ask | 0.3750 x 0 |
Day's Range | 0.3650 - 0.3850 |
52 Week Range | 0.1300 - 0.4200 |
Volume | |
Avg. Volume | 163,331 |
Market Cap | 24.731M |
Beta (5Y Monthly) | 0.41 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1350 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Calgary, Alberta--(Newsfile Corp. - May 16, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce Mr. Richard ("Rick") Groome has joined Hemostemix as a special advisor to the CEO, focused on completing a series of financing transactions. Over the last three decades Mr. Groome was instrumental in creating and building two securities firms, Marleau Lemire and Groome Capital, which funded many successful biotechnology companies."I am
Hemostemix Inc. (V.HEM) hit a new 52-week high of 40 cents Wednesday. No news stories available today. ...
Calgary, Alberta--(Newsfile Corp. - May 10, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has settled all litigation with, and closed the settlement agreement with, Aspire Health Services, Inc., AJIA Global, LLC and Alan Jacobs, Jed Wood, Randi Wood, Blake Wood, Kyle Makofka, Reginald Cooper, and Kingsman Scientific Management. Hemostemix is now in possession of all of its intellectual property, including all HS ...